Corporate Overview

We are a cosmeticeutical company focused on discovering, developing, and commercializing novel drugs for skin care, anti-aging products, weight management, and other cosmetic applications.

Our flagship product is Elite Serum Rx, an internally developed, anti-aging topical cosmeceutical. SkinPro’s staff of specially trained cosmetic pharmacists developed Elite Serum using our proprietary anti-aging peptide formula, which consists of a combination of unique DNA precursor pool peptides.

In addition to the Elite Serum line of products we have discovered and commercialized other scientific breakthroughs in skin care. Our Delfogo Rx line of products consist of some of the most advanced and award winning cosmeceutical innovations in the anti-aging skin care industry. We have launched several other brands including Medical Grade Skin Care, SkinPro, Seductiva and DNA Cosmeceuticals.

Our specially trained cosmetic pharmacists are currently testing new products that represent breakthroughs in the biopharmaceutical industry. Under the DNA Cosmeceuticals brand, our team has developed DNA Serum, which breaks new ground using patented peptides derived from Borneo’s Temple Viper snake venom in a powerful topical anti-aging eye treatment. DNA Serum is currently in the Commercial Phase of our developmental process.



The key elements of our general strategy are as follows:


  • Focus on Elite Serum and Delfogo Rx. We intend to focus our efforts on the continued commercialization of Elite Serum and Delfogo Rx in the United States, Asia and the European Union.
  • Rollout and expand commercialization of Medical Grade Skin Care and SkinPro branded products. Commercialization of Medical Grade Skin Care and SkinPro branded products will rollout to include the European Union, in addition to the United States and North America.
  • Advance our developing products and technologies. We intend to advance our pipeline of product and technology candidates independently or through licensing, collaborations or other opportunities.
  • Maintain research and development capabilities to advance our pipeline. Our technologies, our cosmeceutical discovery infrastructure, and the integrated approach to research used by our scientists have allowed us to identify and develop a number of targets and novel compounds. We intend to maintain our research and development capabilities to selectively advance our programs and to discover additional cosmetic applications and technologies.